Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Ki Won | - |
dc.contributor.author | Choi, Jin Hee | - |
dc.contributor.author | Lee, Soo Yong | - |
dc.contributor.author | Lee, Sang Hyun | - |
dc.contributor.author | Chon, Min Ku | - |
dc.contributor.author | Lee, Jungkuk | - |
dc.contributor.author | Kim, Hasung | - |
dc.contributor.author | Kim, Yong-Giun | - |
dc.contributor.author | Choi, Hyung Oh | - |
dc.contributor.author | Kim, Jeong Su | - |
dc.contributor.author | Park, Yong-Hyun | - |
dc.contributor.author | Kim, June Hong | - |
dc.contributor.author | Chun, Kook Jin | - |
dc.contributor.author | Nam, Gi-Byoung | - |
dc.contributor.author | Choi, Kee-Joon | - |
dc.date.accessioned | 2023-05-25T07:41:10Z | - |
dc.date.available | 2023-05-25T07:41:10Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1471-2261 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22511 | - |
dc.description.abstract | BackgroundEvidence and guidelines for Non-vitamin K antagonist oral anticoagulants (NOACs) use when prescribing concurrent rifampin for tuberculosis treatment in patients with non-valvular atrial fibrillation (NVAF) are limited.MethodsUsing the Korean National Health Insurance Service database from January 2009 to December 2018, we performed a population-based retrospective cohort study to assess the net adverse clinical events (NACE), a composite of ischemic stroke or systemic embolism and major bleeding, of NOACs compared with warfarin among NVAF patients taking concurrent rifampin administration for tuberculosis treatment. After a propensity matching score (PSM) analysis, Cox proportional hazards regression was performed in matched cohorts to investigate the clinical outcomes.ResultsOf the 735 consecutive patients selected, 465 (63.3%) received warfarin and 270 (36.7%) received NOACs. Among 254 pairs of patients after PSM, the crude incidence rate of NACE was 25.6 in NOAC group and 32.8 per 100 person-years in warfarin group. There was no significant difference between NOAC and warfarin use in NACE (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.48-1.14; P = 0.172). Major bleeding was the main driver of NACE, and NOAC use was associated with a statistically significantly lower risk of major bleeding than that with warfarin use (HR, 0.63; 95% CI, 0.40-1.00; P = 0.0499).ConclusionsIn our population-based study, there was no statically significant difference in the occurrence of NACE between NOAC and warfarin use. NOAC use may be associated with a lower risk of major bleeding than that with warfarin use. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/s12872-023-03212-z | - |
dc.identifier.scopusid | 2-s2.0-85151800500 | - |
dc.identifier.wosid | 000963028100001 | - |
dc.identifier.bibliographicCitation | BMC Cardiovascular Disorders, v.23, no.1 | - |
dc.citation.title | BMC Cardiovascular Disorders | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | EDOXABAN | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | Anticoagulation | - |
dc.subject.keywordAuthor | Rifampin | - |
dc.subject.keywordAuthor | Drug-drug interactions | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.